Hematol Oncol: Differential expression of estrogen receptor-alpha in follicle tree cells in patients with level 1-2 and level 3 follicular lymphoma

Hormone therapy has been used in patients with estrogen receptor alpha (ER alpha) positivebreast cancerRecently, a number of studies have reported on the expression of ER alpha in tumor cellsB cellslymphomaHowever, there is only one report on the expression of ER alpha in the follicle dendritic cell (FDCs), which supports the microenvironment of follicular lymphoma (FLs) in structure and functionThe purpose of this study was to investigate the frequency of expression of ER alpha on FDCs in non-tumor reactive lymphatic tissue, and to compare the frequency of expression of ER alpha on FDCs in patients with anti-estrogen therapy and non-oestrogen-free therapy, and in patients with FL level 1-3use reverse transcription-polymerase chain reactions to detect ER alphamRNA in FLER alpha is expressed in the light region in non-tumor reproductive centers (GCs) in patients with tonsillitis or reactive lymphatic adalitisER alpha-positive cells are strongly associated with the widths of GCs (rs s 0.81, P 0.01) and CD21-positive (rs - 0.69, P 0.01) and CD23-positive (rs s .83, P 0.01) FDC mesh structuresThe e-rand-alpha-positive cells of the armpit lymph nodes are fewer, the GC is smaller, and the CD21 and CD23-positive FDC mesh structures are slacker than when hormone-free treatment (P 0.01)G1-2 FL's newborn follicles have more ER alpha-positive cells and larger CD23-FDC mesh structures (P 0.01) than g3 FL's newborn folliclesER alpha mRNA was detected in both G1-2 FL and G3 FL by reverse transcription polymerase chain reactionin general, these results suggest that anti-estrogen hormone therapy can reduce the number of ER alpha-positive FDc, and that estrogen-ER-alpha interactions may react differently to FDC-mediated responses between G1-2 FL and G3 FL